Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia
暂无分享,去创建一个
L. Cuzin | M. Alvarez | C. Récher | M. Attal | S. Cassaing | J. Giron | F. Huguet | L. Têtu | X. Verdeil | A. Chabrol | M. Linas
[1] H. Dombret,et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Patricia Muñoz,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] B. Thiers. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia , 2008 .
[4] G. Wassmer,et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). , 2007, The Journal of infection.
[5] J. Reiffers,et al. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results , 2007, Haematologica.
[6] Philippe Broët,et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. , 2007, Blood.
[7] C. Lass‐Flörl,et al. Primary antifungal prophylaxis in leukaemia patients , 2007 .
[8] C. Heussel,et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] J. Perfect,et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.
[10] Peter G. Pappas,et al. Invasive Fungal Pathogens: Current Epidemiological Trends , 2006 .
[11] F. Lucht,et al. Efficacy of environmental measures to decrease the risk of hospital-acquired aspergillosis in patients hospitalised in haematology wards. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[12] P. Gastmeier,et al. Nosocomial aspergillosis in outbreak settings. , 2006, The Journal of hospital infection.
[13] P. Polgreen,et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. , 2006, Diagnostic microbiology and infectious disease.
[14] H. Dombret,et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia , 2006, Leukemia.
[15] L. Pagano,et al. Design and Methods , 2022 .
[16] S. Koscielny,et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Richard Sylvester,et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.
[18] C. Maslo,et al. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. , 2002, The Journal of hospital infection.
[19] F. Derouin,et al. Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients. , 2001, The Journal of hospital infection.
[20] J. Rowe,et al. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: Before and after chemoprophylaxis and institution of HEPA filters , 2001, American journal of hematology.
[21] S J Lin,et al. Aspergillosis case-fatality rate: systematic review of the literature. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] L. Mannone,et al. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[23] M. Slovak,et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.
[24] A. van Belkum,et al. Density and Molecular Epidemiology ofAspergillus in Air and Relationship to Outbreaks ofAspergillus Infection , 1999, Journal of Clinical Microbiology.
[25] K. Do,et al. Interaction of Granulocytopenia and Construction Activity as Risk Factors for Nosocomial Invasive Filamentous Fungal Disease in Patients With Hematologic Disorders , 1990, Infection Control & Hospital Epidemiology.